Agenda

Preliminary Agenda   

Image result for under construction image

Monday, April 15 2019

09:10 am - 09:35 am
Opening Remarks

Ned Sharpless, MD, National Cancer Institute

09:35 am - 10:10 am
Keynote Presentation: T-cell Co-stimulation in Autoimmune Diseases and Cancer

Arlene H. Sharpe, MD, PhD, Harvard University

 

GASTRONINTESTINAL TOXICITES

SESSION MODERATOR: MICHAEL DOUGAN, MD, PHD

 

10:10 am - 10:30 am
GI Toxicities of Checkpoint Blockade

Michael Dougan, MD, PhD, Massachusetts General Hospital

10:30 am - 10:50 am
Pancreatic Exocrine Related Diarrhea

Gal Markel, MD, PhD, Sheba Medical Center,
Tel Aviv

10:50 am - 11:10 am
Gastrointestinal and Hepatic Complications of Immuno Checkpoint Inhibitors

Robert S. Bresalier, MD, MD Anderson Cancer Center

11:10 am - 11:40 am
PANEL DISCUSSION

 

MOONSHOT ADMINISTRATIVE SUPPLEMENT AWARDEE UPDATE

11:25 am - 11:50 am
Disruption of T cell tolerance in type 1 diabetes

Mark Anderson, MD, PhD, University of California, San Francisco

11:50 am - 01:05 pm
LUNCH BREAK

 

STEROID RESISTANCE/REFRACTIORINESS

01:05 pm - 01:30 pm
IVIG vs. Inflixumab - steroid refractory pneumonitis

Jarushka Naidoo, MBBCh, Johns Hopkins University

01:30 pm - 01:55 pm
Multidisciplinary irAE models

Kelly Walkovich, MD, C. S. Mott Children’s Hospital

 

NEUROLOGICAL AND OCULAR TOXICITIES

SESSION MODERATOR: DAVID HAFLER, MD, FANA

01:55 pm - 02:15 pm
Unleashing the immune system in the brain

David Hafler, MD, FANA, Yale School of Medicine

02:15 pm - 02:35 pm
Severe cases of neuro-toxicity associated with immune checkpoint treatment, strategies employed

Bianca D. Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center

02:35 pm - 02:55 pm
Ocular Toxicities

Hatice Nida Sen, MD, MHS, National Eye Institute

02:55 pm - 03:20 pm
PANEL DISCUSSION
03:20 pm - 03:40 pm
BREAK

 

 

 

COMBINATION THERAPIES

SESSION MODERATOR: ELIZABETH JAFFEE, MD

03:40 pm - 04:10 pm
Keynote presentation: IO combination clinical trials

Elizabeth M. Jaffee, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

04:10 pm - 04:30 pm
Toxicities of radiation-immunotherapy combinations

Jonathan D. Schoenfeld, MD, MPhil, MPHD, Dana-Farber Cancer Institute

04:30 pm - 04:40 pm
Regulatory perspective

Nicole Drezner, MD, U.S. Food and Drug Administration

04:40 pm - 05:15 pm
PANEL DISCUSSION
05:15 pm - 06:45 pm
POSTER SESSION & RECEPTION

 

ADJOURN

Tuesday, April 16 2019

09:00 am - 09:05 am
Welcome and Tribute to Stephen Katz

 

SKIN TOXICITIES AND RHEUMATOLOGY 

SESSION MODERATOR: ROBERT CARTER, MD

09:05 am - 09:25 am
Rheumatic adverse effects of immune checkpoint inhibitors

Xavier Mariette, MD, PhDBicetre Hospital, Paris-Sud University

09:25 am - 09:45 am
Sicca as a complication of immune checkpoint inhibition: Is it Sjögren’s Syndrome?

 Blake Warner, DDS, PhD, MPH, National Institute of Dental and Craniofacial Research

09:45 am - 10:05 am
Skin toxicities from immune checkpoint inhibitors

Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute

10:05 am - 10:25 am
Mechanisms of autoimmunity association with cancer

Antony Rosen, MBChB, MD, Johns Hopkins Medicine

10:25 am - 10:50 am

 

PANEL DISCUSSION

10:50 am - 11:10 am

 

BREAK

 

MOONSHOT ADMINISTRATIVE SUPPLEMENT

AWARDEE UPDATE

11:10 am - 11:35 am
Regulation and function of nonlymphoid organ CD103 dendritic cells

Stephanie Watowich, PhD, MD Anderson Cancer Center

 

META-ANALYSES

SESSION MODERATOR: GIORGIO TRINCHIERI, MD

 

11:35 am - 11:55 am
Immune-related adverse events

Douglas B. Johnson, MD, Vanderbilt-Ingram Cancer Center

11:55 am - 12:15 pm
Regulatory perspective

Meredith Chuk, MD, U.S. Food and Drug Administration

12:15 pm - 01:35 pm

 

LUNCH BREAK

 

KEYNOTE ADDRESS

01:35 pm - 02:05 pm
Microbiome immune-related adverse events

Jennifer Wargo, MD, MMSc, MD Anderson Cancer Center

 

02:05 pm - 02:35 pm

 

PANEL DISCUSSION

META-ANALYSES SPEAKERS AND

DR. WARGO

 

CELL-BASED IMMUNOTHERAPY

02:35 pm - 03:00 pm
Adverse events of CAR-T cell therapy for hematologic malignancies

David L. Porter, MD, University of Pennsylvania Perelman School of Medicine

03:00 pm - 03:25 pm
CAAR-T for pemphigus vulgaris

Michael Milone, MD, PhD, University of Pennsylvania Perelman School of Medicine

03:25 pm - 03:45 pm

 

BREAK

 

PRE-CLINICAL MODELS

SESSION MODERATORS: JULIE SCHNEIDER, PHD AND 

JOHN LEIGHTON, PHD

03:45 pm - 04:05 pm
Autoimmunity following cancer treatment, more questions than answers

Jeff Bluestone, PhD, Parker Institute for Cancer Immunotherapy

04:05 pm - 04:25 pm
Evaluating IO toxicities in syngeneic immunocompetent mouse models: Lessons, opportunities and challenges

Gregory L. Beatty, MD, PhD, University of Pennsylvania

04:25 pm - 04:45 pm
Human CTLA-4 knock-in mouse model for irAE: Mechanism and treatment

Pan Zheng, MD, PhD, University of Maryland, Baltimore

04:45 pm - 05:05 pm
Immune-mediated adverse events in humanized mice receiving checkpoint inhibitors

Kristina E. Howard, DVM, PhD, U.S. Food and Drug Administration

05:05 pm - 05:30 pm

 

PANEL DISCUSSION

 

WRAP-UP AND ADJOURN